Palo Alto-based healthcare AI startup RISA Labs has raised $11.1 million in a Series A funding round co-led by Cencora Ventures and Optum Ventures. The investment highlights growing interest in AI-driven solutions designed for complex medical workflows.
Founded in June 2024 by Kshitij Jaggi and Kumar Shivang, RISA Labs is focused on solving one of the most challenging aspects of healthcare: administrative complexity in oncology.
Meet BOSS: AI for Oncology Workflows
RISA Labs’ core product, BOSS, is an AI-powered platform built to streamline cancer care operations. Oncology treatment involves highly complex processes, including multi-drug therapies, strict insurance requirements, and disease-specific protocols.
BOSS breaks down these workflows into smaller, manageable tasks handled by AI agents. This allows doctors and clinical teams to reduce time spent on administrative work and focus more on patient care.
Strategic Backing and Expansion Plans
The funding round also saw participation from Oncology Ventures, z21 Ventures, and John Simon through VentureForGood. With strong backing from investors experienced in healthcare systems, RISA Labs plans to expand its presence across cancer clinics, health systems, and specialty pharmacies in the United States.
The newly raised capital will primarily be used to scale product deployment and strengthen partnerships within the oncology ecosystem.
Why This Matters
RISA Labs reflects a broader shift in artificial intelligence adoption within healthcare. Instead of building generic AI tools, startups are now creating highly specialized solutions for specific medical fields.
By focusing deeply on oncology, RISA Labs is addressing what many describe as the “administrative burden” in cancer care, a challenge that directly impacts efficiency and patient outcomes.
With investors like Cencora and Optum Ventures, the company is well-positioned to grow in a sector where precision, compliance, and workflow efficiency are critical.
Key Takeaway
RISA Labs is part of a new wave of startups building highly specialized AI solutions. By focusing on oncology, the company is aiming to reduce complexity in one of healthcare’s most demanding areas while improving efficiency for providers.
